Comparative Pharmacology
Head-to-head clinical analysis: ALYACEN 1 35 versus ELIFEMME.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALYACEN 1 35 versus ELIFEMME.
ALYACEN 1/35 vs ELIFEMME
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Elifemme is a small-molecule inhibitor of the bromodomain and extraterminal (BET) family of proteins, specifically BRD4. It disrupts the interaction between BET proteins and acetylated histones, thereby inhibiting oncogene transcription including MYC and BCL2.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Subcutaneous injection: 0.5 mL (15 mg) once weekly.
None Documented
None Documented
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Terminal elimination half-life is 24-30 hours, allowing once-daily dosing for treatment of relapsed/refractory multiple myeloma.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Primarily unchanged in feces (approx. 60-70%) via biliary excretion, with renal excretion accounting for <10% of the dose.
Category C
Category C
Oral Contraceptive
Oral Contraceptive